View source for Zolpidem detailed information

{{drugbox |
| IUPAC_name = N,N,''6-trimethyl-2-(4-methylphenyl)-<BR>imidazo(1,2-''a'')pyridine-3-acetamide''
| image = Zolpidem.png
| image2 = Ambien3dd.png
| width = 200
| CAS_number = 82626-48-0
| ATC_prefix = N05
| ATC_suffix = CF02
| PubChem = 5732
| DrugBank = APRD00095
| C=19 | H=21 | N=3 | O=1 
| molecular_weight = 307.395 [[gram|g]]/[[mole (unit)|mol]]
| bioavailability = 70% (oral) 92% bound in plasma
| metabolism = [[Liver|Hepatic]] CYP34A
| elimination_half-life = 2 to 2.6 hours
| excretion = 56% [[Kidney|renal]]<br />34% [[faeces|faecal]]
| pregnancy_AU = B3
| pregnancy_US = B
| legal_status = [[Misuse of Drugs Act 1971#Class C drugs|Class C]] / POM ([[United Kingdom|UK]])
| legal_US = Schedule IV
| routes_of_administration = Oral
| formulations = Ambien: 5mg tablet, 10mg tablet; Stilnox: 10 mg tablet
}}


'''Zolpidem''' is a prescription short-acting [[nonbenzodiazepine]] hypnotic that potentiates [[gamma-aminobutyric acid]] (GABA), an inhibitory neurotransmitter, by binding to [[benzodiazepine]] receptors which are located on the [[gamma-aminobutyric acid]] receptors.<ref name="pmid17049955">{{cite journal | author = Lemmer B | title = The sleep-wake cycle and sleeping pills | journal = Physiol. Behav. | volume = 90 | issue = 2-3 | pages = 285–93 | year = 2007 | pmid = 17049955 | doi = 10.1016/j.physbeh.2006.09.006 | issn = }}</ref> Zolpidem is used for the short-term treatment of [[insomnia]]. It works quickly (usually within 15 minutes) and has a short [[Elimination half-life|half-life]] (2-3 hours). Some trade names of zolpidem are '''Ambien''',<ref>{{cite web |author=Ambien.com |year=2004 |title=AMBIEN® Prescribing Information |work=Information About a Short-term Treatment for Insomnia - Ambien.com Home Page for Health-care Professionals |publisher= Sanofi-Synthelabo Inc. New York, NY 10016 |url=http://www.ambien.com/hcp/index.asp | accessdate=2005-06-27}}</ref> '''Stilnox''',<ref>[http://www.sanofi-aventis.com.au/products/aus_cmi_stilnox.pdf STILNOX (zolpidem tartrate) PRODUCT INFORMATION] Sanofi-Synthelabo Australia Pty Limited. [[15 April]] [[2004]]</ref> '''Stilnoct''', '''Hypnogen''', '''Zolt''', '''Zolfresh''', '''Nimadorm''', '''Sanval''', and '''Myslee'''.<ref>{{cite web |url=http://en.sanofi-aventis.com/group/products/p_group_products_nervous_stilnox.asp?ComponentID=1267&SourcePageID=1207#3 |title=sanofi-aventis : Drugs and Products - CNS - Stilnox®/Ambien®/Myslee® |accessdate=2006-11-22 |date=2006-11-07}}</ref> Its hypnotic effects are similar to those of the benzodiazepine class of drugs, but it is molecularly distinct from the classical benzodiazepine molecule and is actually classified as an [[imidazopyridine]].  [[Flumazenil]], a benzodiazepine receptor antagonist, which is used for benzodiazepine overdose, can also reverse zolpidem's sedative/hypnotic effects.  As an [[anticonvulsant]] and [[muscle relaxant]], the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. <ref name="pmid2871178">{{cite journal | author = Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G | title = Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects | journal = J. Pharmacol. Exp. Ther. | volume = 237 | issue = 2 | pages = 649–58 | year = 1986 | pmid = 2871178 | doi = | issn = | url = http://jpet.aspetjournals.org/cgi/content/abstract/237/2/649 }}</ref> For that reason, it has never been approved for either muscle relaxation or seizure prevention.  Such drastically increased doses are more inclined to induce one or more negative side effects, including hallucinations and/or amnesia.  (See [[#Side-effects|below]].)

The patent 4382938 in the United States on zolpidem was held by the French pharmaceutical corporation [[Sanofi-Aventis]]. On April 23, 2007 the US FDA approved 13 generic versions of zolpidem tartrate. Zolpidem is available from several generic manufacturers in the UK, as generic from Sandoz in South Africa, as well as from other manufacturers such as ratiopharm.

Recently, zolpidem has been cited in various medical reports mainly in the [[United Kingdom]] as waking [[persistent vegetative state]] (PVS) patients, and dramatically improving the conditions of people with [[Brain injury|brain injuries]].<ref name="pmid10721397">{{cite journal | author = Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR | title = Extraordinary arousal from semi-comatose state on zolpidem. A case report | journal = S. Afr. Med. J. | volume = 90 | issue = 1 | pages = 68–72 | year = 2000 | pmid = 10721397 | doi = | issn = }}</ref><ref>{{cite news |title=Pill 'reverses' vegetative state |url=http://news.bbc.co.uk/1/hi/health/5008744.stm |publisher=BBC |date=2006-05-23 |accessdate=2006-11-20}}</ref><ref>{{cite news |first=Helen |last=Pidd |title=Reborn |url=http://www.guardian.co.uk/medicine/story/0,,1870279,00.html |publisher=the Guardian |date=2006-09-12 |accessdate=2006-11-20}}</ref><ref>{{cite news |first=Clare last=Dyer |title=Judge rejects right-to-die plea by family |url=http://society.guardian.co.uk/health/news/0,,1952341,00.html |publisher=The Guardian |date=2006-11-20 |accessdate=2006-11-20}}</ref><ref>{{cite news |first=Dan |last=Childs |title=Could a Sleeping Pill 'Wake Up' Coma Patients? |url=http://abcnews.go.com/Health/story?id=2947406&page=1 |publisher=ABC News |date=2007-03-13 |accessdate=2007-03-14}}</ref>

== Uses ==
Zolpidem is approved for the short-term (usually two to six weeks) treatment of insomnia, and it has been studied for nightly use up to six months in a single-blind trial published in 1991,<ref name="pmid1670039">{{cite journal | author = Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ | title = Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients | journal = J. Int. Med. Res. | volume = 19 | issue = 3 | pages = 271–9 | year = 1991 | pmid = 1670039 | doi = | issn = }}</ref> an open-label study lasting 180 days published in 1992 (with continued efficacy in patients who had kept taking it as of 180 days after the end of the trial), <ref name="pmid1521672">{{cite journal | author = Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL | title = The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice | journal = J. Int. Med. Res. | volume = 20 | issue = 2 | pages = 162–70 | year = 1992 | pmid = 1521672 | doi = | issn = }}</ref> and in an open-label trial lasting 179 days published in 1993.<ref name="pmid8112475">{{cite journal | author = Kummer J, Guendel L, Linden J, Eich FX, Attali P, Coquelin JP, Kyrein HJ | title = Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia | journal = J. Int. Med. Res. | volume = 21 | issue = 4 | pages = 171–84 | year = 1993 | pmid = 8112475 | doi = | issn = }}</ref>

The [[United States Air Force]] uses zolpidem, under trade name Ambien, as "no-go pills" to help pilots sleep after a mission; another drug used for the same purpose is [[temazepam]] (Restoril).<ref name="pmid16018329">{{cite journal | author = Caldwell JA, Caldwell JL | title = Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures | journal = Aviation, space, and environmental medicine | volume = 76 | issue = 7 Suppl | pages = C39–51 | year = 2005 | pmid = 16018329 | doi = | issn = | url = http://www.ingentaconnect.com/content/asma/asem/2005/00000076/A00107s1/art00010}}</ref> (''Cf.'' the "go-pills" [[amphetamine]], served under the name [[Dexedrine]], or its recent [[modafinil]] (Provigil) replacement, act as a stimulant for the same pilots, the effects of which are reversed by the aforementioned "no-go pills")<ref>[[#endnote no go|''see'' Caldwell ''et al.'', 1993.]]</ref>

Zolpidem is also used [[off-label]] to treat [[restless leg syndrome]] and, as is the case with many prescription sedative/hypnotic drugs, it is sometimes used by stimulant users to "come down" after the use of stimulants such as [[methamphetamine]], [[cocaine]], [[methylenedioxymethamphetamine|MDMA]] (ecstasy), or [[amphetamine]].<ref name="pmid14722823">{{cite journal | author = Evidente VG, Caviness JN, Adler CH | title = Case studies in movement disorders | journal = Seminars in neurology | volume = 23 | issue = 3 | pages = 277–84 | year = 2003 | pmid = 14722823 | doi = 10.1055/s-2003-814739 | issn = }}</ref>

Recently, the drug has been reported anecdotally to have positive effects for patients in [[persistent vegetative state]].<ref name=pmid10721397/>  Results from phase IIa trials are expected in June 2007.  The trials are being conducted by Regen Therapeutics of the UK, who have a patent pending on this new use for Zolpidem.<ref>"[http://news.bbc.co.uk/1/hi/health/5008744.stm Pill 'reverses' vegetative state]" BBC News, 23 May 2006, retrieved 20 June 2007.</ref><ref>[http://pharmalicensing.com/company/disprelease/1152191683_44ad0cc3dc073 Pharmalicensing.com], retrieved 20 June 2007.</ref>

A clinical trial on a single patient performed at the Toulouse University Hospital using [[Positron emission tomography|PET]] shows that zolpidem repeatably improves brain function and mobility of a patient immobilized by akinetic mutism caused by hypoxia.<ref name=Brefel-Courbon>Christine Brefel-Courbon et al (2007). [http://www3.interscience.wiley.com/cgi-bin/abstract/114183274/ABSTRACT Clinical and Imaging Evidence of Zolpidem Effect in Hypoxic Encephalopathy] ''Annals of Neurology'', March 15 2007. [http://www.medscape.com/viewarticle/553513 Medscape summary] Retrieved [[2007-06-12]].</ref>

== Mechanism of action ==
[[Image:Zolpidem DOJ.jpg|frame|right]]Zolpidem binds with high affinity to the [[GABA A receptor|α]]<sub>1</sub> containing GABA<sub>A</sub> receptors, about 10-fold lower affinity for those containing the α<sub>2</sub>, α<sub>3</sub>-[[GABA A receptor|GABA<sub>A</sub> receptor]] subunits, and with no appreciable affinity for α<sub>5</sub> subunit containing receptors.<ref name="pmid2157817">{{cite journal | author = Pritchett DB, Seeburg PH | title = Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology | journal = J. Neurochem. | volume = 54 | issue = 5 | pages = 1802–4 | year = 1990 | pmid = 2157817 | doi = 10.1111/j.1471-4159.1990.tb01237.x | issn = }}</ref> 

Like the vast majority of benzodiazepine like molecules, zolpidem has no affinity for α<sub>4</sub> and α<sub>6</sub> subunit containing receptors.<ref name="pmid8794909">{{cite journal | author = Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ | title = Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit | journal = Mol. Pharmacol. | volume = 50 | issue = 3 | pages = 670–8 | year = 1996 | pmid = 8794909 | doi = | issn = | url = http://molpharm.aspetjournals.org/cgi/content/abstract/50/3/670 }}</ref> Zolpidem positively modulates GABA<sub>A</sub> receptors, probably by increasing the GABA<sub>a</sub> receptor complexes apparent affinity for GABA, without effect desensitization, or peak current.<ref name="pmid9880578">{{cite journal | author = Perrais D, Ropert N | title = Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses | journal = J. Neurosci. | volume = 19 | issue = 2 | pages = 578–88 | year = 1999 | pmid = 9880578 | doi = | issn = | url = http://www.jneurosci.org/cgi/content/abstract/19/2/578 }}</ref> Zolpidem increases slow wave sleep and caused no effect on stage 2 sleep in laboratory tests.<ref name="pmid15037809">{{cite journal | author = Noguchi H, Kitazumi K, Mori M, Shiba T | title = Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats | journal = J. Pharmacol. Sci. | volume = 94 | issue = 3 | pages = 246–51 | year = 2004 | pmid = 15037809 | doi = 10.1254/jphs.94.246| issn = }}</ref>

A [[meta-analysis]] of the randomised controlled [[clinical trials]] which compared benzodiazepines against Z drugs has shown that there are few consistent differences between zolpidem and [[benzodiazepines]] in terms of sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia and daytime alertness.<ref name="pmid15252823">{{cite journal | author = Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T | title = Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis | journal = Human psychopharmacology | volume = 19 | issue = 5 | pages = 305–22 | year = 2004 | pmid = 15252823 | doi = 10.1002/hup.594 | issn = }}</ref>

== Recreational use and abuse ==


Zolpidem recreational users may take the drug orally, crush and snort it, or cook it for an intravenous injection. Intravenous use is especially hazardous as doses as low as 5mg can produce complete unconsciousness within seconds. The transition from medicinal use to recreational use of Zolpidem can occur when used longer than recommended (no longer than a few weeks), at high doses (more than the usual 10mg), and in people who have been dependent on other drugs or alcohol in the past. Zolpidem effects can increase and intensify if mixed with other substances like alcohol.

Recreational use of this drug (specifically the Ambien brand) is becoming more common in young people. Recreational users claim that "fighting" the effects of the drug by forcing themselves to stay awake will sometimes cause vivid visuals and a body high (see side-effects below). However, in some people who are already in an anxious state, or suffer from neurosis it is not hard, if a struggle at all, to fight the main effect of sedation, experiencing the side-effect of euphoria more than the sedation itself.  Thus some users report decreased anxiety, and even mild [[Euphoria (emotion)|euphoria]], as well as perceptual changes, visual distortions, and light-based hallucinations. Auditory distortions have been reported in some users. Odd behavior, confusion, and loss of balance have been reported among the various effects of the drug.

To counteract recreational use of zolpidem in the United States, Sanofi-Aventis coats their pills with a flexible plastic-like coating, which sticks to unpulverized "bumps" or "chunks" and can be difficult to remove, thus hindering the process of [[insufflation]]; although this is a relatively minor obstacle to an experienced recreational drug user.

With high dose regular use or abuse of zolpidem there can be a risk of a severe physical dependence on zolpidem with cases being reported in the medical literature of epileptic seizures forming part of the withdrawal syndrome. One case involved a woman detoxing off a high dose of zolpidem experiencing a generalised seizure. The clinical withdrawal and dependence effects were reported to be similar to those of benzodiazepines in this case report.<ref name="pmid16950552">{{cite journal | author = Cubała WJ, Landowski J | title = Seizure following sudden zolpidem withdrawal | journal = Prog. Neuropsychopharmacol. Biol. Psychiatry | volume = 31 | issue = 2 | pages = 539–40 | year = 2007 | pmid = 16950552 | doi = 10.1016/j.pnpbp.2006.07.009 | issn = }}</ref>

Zolpidem and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other drugs including the benzodiazepines and [[zopiclone]] are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range suggesting a high degree of excessive-use potential for [[benzodiazepines]], zolpidem and [[zopiclone]].<ref name="pmid17417081">{{cite journal | author = Jones AW, Holmgren A, Kugelberg FC | title = Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results | journal = Therapeutic drug monitoring | volume = 29 | issue = 2 | pages = 248–60 | year = 2007 | pmid = 17417081 | doi = 10.1097/FTD.0b013e31803d3c04 | issn = }}</ref>

As Ambien's patent expired April 21, 2007, new generic versions were approved, which do not have the "protective cover" present on the Sanofi name-brand Ambien.

==Dependence and withdrawal==
Alcohol has cross tolerance with GABAa receptor positive modulators such as the [[benzodiazepines]] and the [[nonbenzodiazepine]] drugs. For this reason alcoholics or recovering alcoholics may be at increased risk of [[physical dependency]] on zolpidem. Also, alcoholics and drug abusers may be at increased risk of abusing and or becoming psychologically dependent on zolpidem. Zolpidem should be avoided in those with a history of [[Alcoholism]], [[drug misuse]] (illicit or prescription misuse), or in those with history of [[physical dependency]] or [[psychological dependency]] on sedative-hypnotic drugs.

==Overdose==
Overdose of zolpidem may present with excessive sedation, pin-point pupils, depressed respiratory function, which may progress to coma and possibly death. Zolpidem combined with alcohol, opiates or other [[Central nervous system|CNS]] depressants may be even more likely to lead to fatal overdoses. Zolpidem overdosage can be treated with the benzodiazepine receptor antagonist [[flumazenil]] which displaces zolpidem from its binding site the benzodiazepine receptor and therefore rapidly reverses the effects of zolpidem.<ref name="pmid2111156">{{cite journal | author = Lheureux P, Debailleul G, De Witte O, Askenasi R | title = Zolpidem intoxication mimicking narcotic overdose: response to flumazenil | journal = Human & experimental toxicology | volume = 9 | issue = 2 | pages = 105–7 | year = 1990 | pmid = 2111156 | doi = | issn = }}</ref>

== Side-effects ==

Side effects at any dose may include:

* [[Anterograde amnesia]]  
* [[Hallucination]]s, through all physical senses, of varying intensity
* [[Delusion]]s
* Altered thought patterns
* [[Ataxia]] or poor [[motor coordination]], difficulty maintaining balance<ref name="pmid16045197">{{cite journal | author = Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, Tai N, Shinohara S, Tokomura M, Horiuchi M, Abe K | title = [Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes] | language = Japanese | journal = Nihon Shinkei Seishin Yakurigaku Zasshi &#61; Japanese Journal of Psychopharmacology | volume = 25 | issue = 3 | pages = 143–51 | year = 2005 | pmid = 16045197 | doi = | issn = }}</ref>
* [[Euphoria (emotion)|Euphoria]] and/or [[dysphoria]]
* Increased appetite
* Decreased [[libido]] 
* [[Amnesia]]
* Impaired judgment and reasoning  
* Uninhibited [[extroversion]] in social or interpersonal settings
* Increased impulsivity
* When stopped rebound insomnia may occur

Some users take zolpidem recreationally for these side effects. However, it may be less common than [[benzodiazepine]] abuse. In the United States, recreational use may be less common than in countries where the drug is available as a less expensive generic (or in countries, such as the UK, where prescriptions are free or heavily subsidised). It is not yet known whether there is a link between the cost and availability of zolpidem and the level at which it is abused.  Zolpidem can become [[addictive]] if taken for extended periods of time, due to dependence on its ability to put one to sleep or to the [[Euphoria (emotion)|euphoria]] it can sometimes produce. Like most addictive drugs, a tolerance in the zolpidem user develops and increases all the more quickly the longer the user has been regularly taking it. Under the influence of the drug it is common to take more zolpidem than is necessary due to either forgetting that one has already taken a pill (elderly users are particularly at risk here), or knowingly taking more than the prescribed dosage. Users with a predilection for abuse are advised to keep additional zolpidem in a safe place that is unlikely to be remembered or accessed while intoxicated to avoid this risk. A trustworthy friend or relative is the best defense if such people are available; otherwise, a box or cupboard locked with a combination padlock is a good defense against this tendency, as the above-mentioned side-effects can easily prevent a user from operating such a lock while under the drug's influence. The recent release of Ambien CR® (zolpidem tartrate extended release) in the United States renewed interest in the drug among recreational drug users.

Before a user becomes fully acclimated to these effects (or if the user does not become acclimated), these symptoms can be severe enough to be deemed as drug-induced [[psychosis]]. Incidentally, [[antipsychotics]] like [[ziprasidone]] (Geodon®) or [[quetiapine]] (Seroquel®) may be prescribed alongside zolpidem to both combat these side effects and to aid in sleep-induction, as both of them contain mild hypnotic properties. However, because some antidepressants are known for being mildly sedating (i.e., [[paroxetine]]), it may be inadvisable to use zolpidem and an antidepressant simultaneously. Some zolpidem users (especially those suffering from chronic insomnia), however, commonly use these drug combination due to the relative ease with which the user gains no benefit from one or the others of these drugs, while both together can assist sufferers of insomnia in getting to sleep.

Some users have reported unexplained [[sleepwalking]] while using Ambien, and a few have reported driving,  binge eating, sleep talking, and performing other daily tasks while sleeping. The sleepwalker can sometimes perform these tasks as normally as they might if they were awake. They can sometimes carry on complex conversations and respond appropriately to questions or statements so much so that the observer may believe the sleepwalker to be awake. This is similar to, but unlike typical sleep talking,  which can usually be identified  easily and is characterised by incoherent  speech that often has no relevance to the situation or that is so disorganised as to be completely unintelligible. These statements bear a strong resemblance to that of [[schizophasia]], one of many symptoms commonly seen in individuals suffering from [[schizophrenia]]. A person under the influence of this medication may seem fully aware of their environment even though they are still asleep. This can bring about concerns for the safety of the sleepwalker and others.

Driving while under the drug's influence is generally considered several orders of magnitude more dangerous than the average drunk driver, due to the diminished motor controls and delusions that may affect the user. It is unclear if the drug is responsible for the behavior, but a class-action lawsuit was filed against Sanofi-Aventis in March 2006 on behalf of those who reported symptoms.[http://www.msnbc.msn.com/id/11901810/site/newsweek/] Residual 'hangover' effects such as sleepiness, impaired psychomotor and cognitive after nighttime administration may persist into the next day which may impair the ability of users to drive safely, increase risks of falls and hip fractures.<ref name="pmid15089115">{{cite journal | author = Vermeeren A | title = Residual effects of hypnotics: epidemiology and clinical implications | journal = CNS drugs | volume = 18 | issue = 5 | pages = 297–328 | year = 2004 | pmid = 15089115 | doi = | issn = }}</ref>

More recently, the ''[[Sydney Morning Herald]]'' in Australia reported on 4 March 2007 that a man who fell 30 metres to his death from a high-rise unit balcony may have been sleepwalking under the influence of Stilnox. The coverage prompted over 40 readers to contact the newspaper with their own accounts of Stilnox related automatism and the drug is now under review by the Adverse Drug Reactions Advisory Committee.<ref>{{cite news |first=Heath |last=Gilmore |title=Sleeping pill safety under federal review |url=http://www.smh.com.au/news/national/sleeping-pill-safety-under-federal-review/2007/03/10/1173478729115.html |publisher=the Sydney Morning Herald |date=2007-03-11 |accessdate=2007-03-11}}</ref>

On 6 April 2007 Australia's [[Therapeutic Goods Administration]] ordered the manufacturer to upgrade its warning about mixing the pills with alcohol.[http://www.smh.com.au/news/national/warning-upgrade-over-stilnox-weirdness/2007/04/05/1175366396888.html] 

There are many unsubstantiated reports on the internet of people who have had issues with this medication.[http://www.erowid.org/experiences/subs/exp_Pharms_-_Zolpidem.shtml]

On March 14, 2007, the [[US Food and Drug Administration]] ordered stronger warnings on 13 prescription sleep-hypnotic drugs including zolpidem and [[eszopiclone]]. The dangers of allergic reactions and driving while intoxicated, while serious, are not thought to be sufficient to withdraw the drugs from the market.<ref>{{cite news |first=Susan |last=Heavey |title=FDA orders stronger warnings on sleep drugs |url=http://abcnews.go.com/Health/wireStory?id=2950528 |publisher=ABC News |date=2007-03-14 |accessdate=2007-03-14}}</ref>

In May 2007, Slovenian serial killer Silvo Plut committed suicide by consuming a large quantity of Zolpidem, sold under the brandname Sanval.

The media reports of side effects of Zolpidem have caused them to become referred to in popular culture. In the [[Simpsons]] episode ''[[Crook and Ladder]]'', [[Homer Simpson]] becomes addicted to an insomnia pill known as Nappien and starts experiencing strange side effects. To this, Lisa Simpsons says ''"I've read that people do strange things in their sleep when they've taken Ambien... I mean Nappien."''

== See also ==
* [[Alpidem]]
* [[Imidazopyridine]]

== References==
{{reflist|2}}

==Notes==
# {{note|abuse}}  Angelettie M.S.W., Lisa. "Ambien Abuse" [http://www.bellaonline.com/articles/art22470.asp Fulltext]

==External links==
* [http://www.erowid.org/pharms/zolpidem/zolpidem.shtml Erowid Zolpidem (Ambien) Vault]
* [http://dailymed.nlm.nih.gov/dailymed/fdaDrugXsl.cfm?id=635&type=display Ambien® CIV (zolpidem tartrate)] at the [[National Institute of Health|NIH]] DailyMed website
{{Hypnotics and sedatives}}

[[Category:Anxiolytics]]
[[Category:Hypnotics]]
[[Category:Imidazopyridines]]
[[Category:Sedatives]]

[[de:Zolpidem]]
[[es:Zolpidem]]
[[fr:Zolpidem]]
[[it:Zolpidem]]
[[nl:Zolpidem]]
[[ja:ゾルピデム]]
[[pl:Zolpidem]]
[[pt:Zolpidem]]
[[fi:Tsolpideemi]]
[[sv:Zolpidem]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{jb1}}